The use of mistletoe in cancer is a popular treatment in cancer in many European countries. The common use is by injection given under the skin and there is a growing interest in the intravenous application. I would classify mistletoe as an original “immune-system” treatment that has finally become to the attention of the mainstream oncology community. Clinically we have seen patients with cancer respond to this form of treatment by improving quality of life symptoms such as in pain, appetite, and energy. Furthermore, there are groups where we have documented a cancer-fighting effect. The first patient we personally treated over 10 years ago was with advanced and progressing colon cancer, where the intravenous application of mistletoe stabilized his disease outside of any chemotherapy treatment. This experience opened our minds to the capabilities of this promising therapy.
The below recent study discusses the application and experience of mistletoe given by intravenous treatment to patients with cancer by a group of European physicians. Positive benefits were noted which included cases of patients whose disease was better controlled and more.
To find out more, please follow the below link.
Intravenous Mistletoe Treatment In Integrative Cancer Care 2016
Fasting for up to 72 h, divided as 48 h before and 24 h after chemotherapy infusion, appears safe and feasible in people with cancer receiving platinum-based combination chemotherapy. Preliminary evidence from correlative studies supports that fasting may protect the body and tissues against chemotherapy damage.
Subjects were instructed to consume zero calories, but ample water and non-caloric beverages. However subjects were advised that if they had symptoms related to fasting (such as feeling faint, weak, dizzy, etc.) that they should consume a small amount of juice or food, aiming to stay under 200 kcal in a 24 h period.
The scientific journal article can be found below for further information.
Fasting with Platinum-based Chemotherapy October 2016
In Prostate Cancer, substituting 30 g/day of poultry or fish for total or unprocessed red meat was associated with significantly lower risk of recurrence. Lower intakes of red meat and well-done red meat and higher intakes of poultry and fish are associated with lower risk of high grade and advanced prostate cancer and reduced recurrence risk, independent of stage and grade.
See the published article below:
Diet Changes Lowers Recurrence Outcomes in Prostate Cancer-Sept-2016
We are excited and proud of Sarina Auriel’s new book The HeartFull Way, a step-by-step guide to moving from surviving to thriving. Her program is a gentle and empowering practice for creating healing in individuals, in families and across generations. Following The HeartFull Way it is possible to transform a full life into a life lived fully and from the heart.
Please join the book launch event at the beautiful new Wesbrook Community Centre (UBC) on Thursday, October 20, 2016 from 7 to 9 pm
Please see the below link for further information.
The HeartFullway_Book-Launch-Event Poster
Dr Lemmo’s case report is a leading story in this months Integrative Cancer Therapies journal. It is an honour to have Dr. Keith Block, a respected and pioneering oncologist, comment on our Raloxifene Anti-Estrogen Withdrawal Effect case which was published online in July 2016. In this issue you will also see the more detailed Editorial by Dr. V. Craig Jordan, also known as the “Father of Tamoxifen”, from MD Anderson Cancer Center regarding this case report and his fascinating insights into how a women’s own estrogen can shrink breast cancer even when followed by hormone treatments such as Tamoxifen and related drugs.
Please see the below link to read Dr. Keith Block’s Editorial.
Block-K – Editorial – September Issue 2016 – Integrative-Cancer-Therapies
Join us for a special long table dinner on Thursday, August 11 in the Poplar Grove at The UBC Farm. In collaboration with The Juice Truck and Feedlife, we’re creating a true plant-based ‘Garden of Eden’ meal in honour of Eden Elizabeth to benefit Thrive Alive Foundation; a foundation focused on creating access for Canadians to life-enhancing cancer treatments not traditionally covered by the government or most health care plans.
We will enjoy an epic 5 COURSE MEAL curated by a chef team that has been hand picked by Colin Medhurst (co-founder of Feedlife and plant-based chef): Your headliner is Chef Karen McAthy of Blue Heron Cheese who will announce her final lineup this week! Your dinner ticket includes wine pairing by Red Rooster, cocktails by Design to Dine, beer & live entertainment!
Show up in your Thursdays’ finest (aka: farm chic) and expect the venue to completely blow your farm-to-table, garden of eden dreams out of the water.
The Garden of Eden – Farmacie Event.
A patient with advanced breast cancer experienced a significant shrinkage of her metastatic disease when stopping the drug Raloxifene (a relative of Tamoxifen). She continues to be in excellent shape without the need of any treatment during the past 16 months. The oncology community is largely not aware of this phenomenon where a drug designed to help with breast cancer may do the exact opposite and feed the disease. Senior scientist and researcher Dr. V. Craig Jordan from the University of Texas MD Anderson Cancer Center wanted to place further attention in this area by writing a guest editorial on our case. This has been such an incredible honour and we are truly humbled by Dr. Jordan’s supportive comments. Dr. Jordan shares valuable expertise and insights into a largely unknown area in oncology on how the bodies own estrogen can actually shrink breast cancer and which may be an explanation for the positive response seen in this case report.
To find out more, the scientific article can be found below.
Jordan VC Editorial and Lemmo Raloxifene AEWE Case Report July 13 2016
Dr Lemmo will be speaking on the use of intravenous vitamin C plus some promising technologies in cancer here in Vancouver at the Fairmont Hotel Vancouver on April 30, 2016. Please find out more in the attached brochure.OMT-2016